Recently, the use of SpCas9 to knockout ABCB1 in multidrug-resistant colorectal cancer cells (SW620/Ad300 and HCT-15) has demonstrated restored sensitivity to the ABCB1 substrate drug, doxorubicin (Fig. 3A). This evidence concerns the gene ABCB1 and colorectal cancer.